145 related articles for article (PubMed ID: 32434991)
21. The acinar regulator Gata6 suppresses KrasG12V-driven pancreatic tumorigenesis in mice.
Martinelli P; Madriles F; Cañamero M; Pau EC; Pozo ND; Guerra C; Real FX
Gut; 2016 Mar; 65(3):476-86. PubMed ID: 25596178
[TBL] [Abstract][Full Text] [Related]
22. Loss of the transcriptional repressor TGIF1 results in enhanced Kras-driven development of pancreatic cancer.
Weng CC; Hsieh MJ; Wu CC; Lin YC; Shan YS; Hung WC; Chen LT; Cheng KH
Mol Cancer; 2019 May; 18(1):96. PubMed ID: 31109321
[TBL] [Abstract][Full Text] [Related]
23. EYA4 functions as tumor suppressor gene and prognostic marker in pancreatic ductal adenocarcinoma through β-catenin/ID2 pathway.
Mo SJ; Liu X; Hao XY; Chen W; Zhang KS; Cai JP; Lai JM; Liang LJ; Yin XY
Cancer Lett; 2016 Oct; 380(2):403-412. PubMed ID: 27378242
[TBL] [Abstract][Full Text] [Related]
24. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N
Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203
[TBL] [Abstract][Full Text] [Related]
25. FOXO1-regulated lncRNA LINC01197 inhibits pancreatic adenocarcinoma cell proliferation by restraining Wnt/β-catenin signaling.
Ling J; Wang F; Liu C; Dong X; Xue Y; Jia X; Song W; Li Q
J Exp Clin Cancer Res; 2019 Apr; 38(1):179. PubMed ID: 31027497
[TBL] [Abstract][Full Text] [Related]
26. SOX9 activity is induced by oncogenic Kras to affect MDC1 and MCMs expression in pancreatic cancer.
Zhou H; Qin Y; Ji S; Ling J; Fu J; Zhuang Z; Fan X; Song L; Yu X; Chiao PJ
Oncogene; 2018 Feb; 37(7):912-923. PubMed ID: 29059173
[TBL] [Abstract][Full Text] [Related]
27. MicroRNAs of the mir-17~92 cluster regulate multiple aspects of pancreatic tumor development and progression.
Quattrochi B; Gulvady A; Driscoll DR; Sano M; Klimstra DS; Turner CE; Lewis BC
Oncotarget; 2017 May; 8(22):35902-35918. PubMed ID: 28415794
[TBL] [Abstract][Full Text] [Related]
28. Inducible nitric oxide synthase enhances disease aggressiveness in pancreatic cancer.
Wang J; He P; Gaida M; Yang S; Schetter AJ; Gaedcke J; Ghadimi BM; Ried T; Yfantis H; Lee D; Weiss JM; Stauffer J; Hanna N; Alexander HR; Hussain SP
Oncotarget; 2016 Aug; 7(33):52993-53004. PubMed ID: 27367029
[TBL] [Abstract][Full Text] [Related]
29. BCAT2-mediated BCAA catabolism is critical for development of pancreatic ductal adenocarcinoma.
Li JT; Yin M; Wang D; Wang J; Lei MZ; Zhang Y; Liu Y; Zhang L; Zou SW; Hu LP; Zhang ZG; Wang YP; Wen WY; Lu HJ; Chen ZJ; Su D; Lei QY
Nat Cell Biol; 2020 Feb; 22(2):167-174. PubMed ID: 32029896
[TBL] [Abstract][Full Text] [Related]
30. MicroRNA-214-5p Inhibits the Invasion and Migration of Hepatocellular Carcinoma Cells by Targeting Wiskott-Aldrich Syndrome Like.
Li H; Wang H; Ren Z
Cell Physiol Biochem; 2018; 46(2):757-764. PubMed ID: 29621773
[TBL] [Abstract][Full Text] [Related]
31. Loss of Setd2 promotes Kras-induced acinar-to-ductal metaplasia and epithelia-mesenchymal transition during pancreatic carcinogenesis.
Niu N; Lu P; Yang Y; He R; Zhang L; Shi J; Wu J; Yang M; Zhang ZG; Wang LW; Gao WQ; Habtezion A; Xiao GG; Sun Y; Li L; Xue J
Gut; 2020 Apr; 69(4):715-726. PubMed ID: 31300513
[TBL] [Abstract][Full Text] [Related]
32. The Loss of ATRX Increases Susceptibility to Pancreatic Injury and Oncogenic KRAS in Female But Not Male Mice.
Young CC; Baker RM; Howlett CJ; Hryciw T; Herman JE; Higgs D; Gibbons R; Crawford H; Brown A; Pin CL
Cell Mol Gastroenterol Hepatol; 2019; 7(1):93-113. PubMed ID: 30510993
[TBL] [Abstract][Full Text] [Related]
33. Krüppel-like Factor 5, Increased in Pancreatic Ductal Adenocarcinoma, Promotes Proliferation, Acinar-to-Ductal Metaplasia, Pancreatic Intraepithelial Neoplasia, and Tumor Growth in Mice.
He P; Yang JW; Yang VW; Bialkowska AB
Gastroenterology; 2018 Apr; 154(5):1494-1508.e13. PubMed ID: 29248441
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of Aurora Kinase A Induces Necroptosis in Pancreatic Carcinoma.
Xie Y; Zhu S; Zhong M; Yang M; Sun X; Liu J; Kroemer G; Lotze M; Zeh HJ; Kang R; Tang D
Gastroenterology; 2017 Nov; 153(5):1429-1443.e5. PubMed ID: 28764929
[TBL] [Abstract][Full Text] [Related]
35. KRAS promotes tumor metastasis and chemoresistance by repressing RKIP via the MAPK-ERK pathway in pancreatic cancer.
Yang K; Li Y; Lian G; Lin H; Shang C; Zeng L; Chen S; Li J; Huang C; Huang K; Chen Y
Int J Cancer; 2018 Jun; 142(11):2323-2334. PubMed ID: 29315556
[TBL] [Abstract][Full Text] [Related]
36. YAP1 oncogene is a context-specific driver for pancreatic ductal adenocarcinoma.
Tu B; Yao J; Ferri-Borgogno S; Zhao J; Chen S; Wang Q; Yan L; Zhou X; Zhu C; Bang S; Chang Q; Bristow CA; Kang Y; Zheng H; Wang H; Fleming JB; Kim M; Heffernan TP; Draetta GF; Pan D; Maitra A; Yao W; Gupta S; Ying H
JCI Insight; 2019 Nov; 4(21):. PubMed ID: 31557131
[TBL] [Abstract][Full Text] [Related]
37. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression.
Li Z; Shao C; Liu X; Lu X; Jia X; Zheng X; Wang S; Zhu L; Li K; Pang Y; Xie F; Lu Y; Wang Y
Carcinogenesis; 2020 Mar; 41(1):44-55. PubMed ID: 31046123
[TBL] [Abstract][Full Text] [Related]
38. Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies.
Kim VM; Blair AB; Lauer P; Foley K; Che X; Soares K; Xia T; Muth ST; Kleponis J; Armstrong TD; Wolfgang CL; Jaffee EM; Brockstedt D; Zheng L
J Immunother Cancer; 2019 May; 7(1):132. PubMed ID: 31113479
[TBL] [Abstract][Full Text] [Related]
39. Aspartate β-hydroxylase promotes pancreatic ductal adenocarcinoma metastasis through activation of SRC signaling pathway.
Ogawa K; Lin Q; Li L; Bai X; Chen X; Chen H; Kong R; Wang Y; Zhu H; He F; Xu Q; Liu L; Li M; Zhang S; Nagaoka K; Carlson R; Safran H; Charpentier K; Sun B; Wands J; Dong X
J Hematol Oncol; 2019 Dec; 12(1):144. PubMed ID: 31888763
[TBL] [Abstract][Full Text] [Related]
40. Early requirement of Rac1 in a mouse model of pancreatic cancer.
Heid I; Lubeseder-Martellato C; Sipos B; Mazur PK; Lesina M; Schmid RM; Siveke JT
Gastroenterology; 2011 Aug; 141(2):719-30, 730.e1-7. PubMed ID: 21684285
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
